Clinical Practice Guidelines for diagnosis of amyloidosis: Part 1/3 Year 2020
Method: Use the PICO format to generate a series of questions, focusing on the specificity and sensitivity of the amyloidosis diagnostic test. PubMed searches were conducted in English and Spanish from July to August 2019. The level of evidence and recommendation are based on the GRADE system (http:...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2021
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/30824 |
| Aporte de: |
| id |
I10-R327-article-30824 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
amyloidosis diagnosis amyloidosis inmunoglobulin light-chain amyloidosis amyloidosis, familial Spanish amiloidosis diagnóstico amiloidosis; amiloidosis de cadenas ligeras de las inmunoglobulinas amiloidosis familiar amiloidose diagnóstico amiloidose de cadeia leve de imunoglobulina amiloidose familiar Español |
| spellingShingle |
amyloidosis diagnosis amyloidosis inmunoglobulin light-chain amyloidosis amyloidosis, familial Spanish amiloidosis diagnóstico amiloidosis; amiloidosis de cadenas ligeras de las inmunoglobulinas amiloidosis familiar amiloidose diagnóstico amiloidose de cadeia leve de imunoglobulina amiloidose familiar Español Posadas Martinez, Maria Lourdes Aguirre, María Adela Belziti, Cesar Brouet, Eva Auteri, Miguel Angel Forte, Ana Luz Greloni, Gustavo Marciano, Sebastian Matoso, Maria Dolores Perez de Arenaza, Diego Pitzus, Ariel Edgardo Rugiero, Marcelo Saez, Soledad Sorroche, Patricia Tomei, Mauricio Zinser, Bettina Peuchot, Veronica Nucifora, Elsa Clinical Practice Guidelines for diagnosis of amyloidosis: Part 1/3 Year 2020 |
| topic_facet |
amyloidosis diagnosis amyloidosis inmunoglobulin light-chain amyloidosis amyloidosis, familial Spanish amiloidosis diagnóstico amiloidosis; amiloidosis de cadenas ligeras de las inmunoglobulinas amiloidosis familiar amiloidose diagnóstico amiloidose de cadeia leve de imunoglobulina amiloidose familiar Español |
| author |
Posadas Martinez, Maria Lourdes Aguirre, María Adela Belziti, Cesar Brouet, Eva Auteri, Miguel Angel Forte, Ana Luz Greloni, Gustavo Marciano, Sebastian Matoso, Maria Dolores Perez de Arenaza, Diego Pitzus, Ariel Edgardo Rugiero, Marcelo Saez, Soledad Sorroche, Patricia Tomei, Mauricio Zinser, Bettina Peuchot, Veronica Nucifora, Elsa |
| author_facet |
Posadas Martinez, Maria Lourdes Aguirre, María Adela Belziti, Cesar Brouet, Eva Auteri, Miguel Angel Forte, Ana Luz Greloni, Gustavo Marciano, Sebastian Matoso, Maria Dolores Perez de Arenaza, Diego Pitzus, Ariel Edgardo Rugiero, Marcelo Saez, Soledad Sorroche, Patricia Tomei, Mauricio Zinser, Bettina Peuchot, Veronica Nucifora, Elsa |
| author_sort |
Posadas Martinez, Maria Lourdes |
| title |
Clinical Practice Guidelines for diagnosis of amyloidosis: Part 1/3 Year 2020 |
| title_short |
Clinical Practice Guidelines for diagnosis of amyloidosis: Part 1/3 Year 2020 |
| title_full |
Clinical Practice Guidelines for diagnosis of amyloidosis: Part 1/3 Year 2020 |
| title_fullStr |
Clinical Practice Guidelines for diagnosis of amyloidosis: Part 1/3 Year 2020 |
| title_full_unstemmed |
Clinical Practice Guidelines for diagnosis of amyloidosis: Part 1/3 Year 2020 |
| title_sort |
clinical practice guidelines for diagnosis of amyloidosis: part 1/3 year 2020 |
| description |
Method: Use the PICO format to generate a series of questions, focusing on the specificity and sensitivity of the amyloidosis diagnostic test. PubMed searches were conducted in English and Spanish from July to August 2019. The level of evidence and recommendation are based on the GRADE system (http://www.gradeworkinggroup.org/index.htm). The recommendations are graded according to their direction (for or against) and strength (strong and weak). Finally, it is recommended to use GLIA tools to evaluate the obstacles and facilitators in implementation.
Suggested explanation: A strong suggestion indicates a high degree of trust in support or opposition to the intervention. When defining a strong recommendation, this guide uses the "recommended" language. The weaker recommendations indicate that the outcome of the intervention (favorable or unfavorable) is doubtful. In this case, if a weak recommendation is defined, the "recommendation" language is used.
How to use these guidelines: Recommendations must be explained within the scope of special care in validated diagnostic studies conducted by specially trained doctors. It is not assumed to change the coexistence conditions of the disease process. Presumably, the attending physician has a high degree of suspicion of amyloidosis. It assumes that diagnostic research is conducted by well-trained doctors using a validated standardized method. This guide is intended for health care professionals and those involved in health care policies to help ensure that the necessary agreements have been reached to provide appropriate care.
Recommendations
For patients with suspected amyloidosis, it is recommended:
Confirmation in the tissue by biopsy and Congo red staining with the characteristic green birefringence under polarized light is recommended.
Confirmation by electron microscopy of the biopsy tissue is recommended.
Protein typing by mass spectrometry is recommended.
Protein typing by optical and / or electronic immunomicroscopy is recommended, as long as there are reliable antibodies.
Measurement of serum free light chains is recommended for evaluation of a monoclonal plasma cell proliferative disorder.
Serum and urinary immunofixation is recommended for evaluation of a monoclonal plasma cell proliferative disorder.
Measurement of serum free light chains, plus serum and urinary immunofixation is recommended for the evaluation of a monoclonal plasma cell proliferative disorder.
For patients suspected of having amyloidosis, it is suggested:
Demonstration of a monoclonal plasma cell proliferative disorder by demonstration of clonal plasma cells by the most sensitive technique available in the bone marrow for the diagnosis of AL-type amyloidosis.
Confirmation of ATTRv amyloidosis by DNA sequencing of the 4-exon amyloidogenic TTR gene in patients with suspected ATTRv amyloidosis.
|
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2021 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/30824 |
| work_keys_str_mv |
AT posadasmartinezmarialourdes clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT aguirremariaadela clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT belziticesar clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT broueteva clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT auterimiguelangel clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT forteanaluz clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT grelonigustavo clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT marcianosebastian clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT matosomariadolores clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT perezdearenazadiego clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT pitzusarieledgardo clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT rugieromarcelo clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT saezsoledad clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT sorrochepatricia clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT tomeimauricio clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT zinserbettina clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT peuchotveronica clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT nuciforaelsa clinicalpracticeguidelinesfordiagnosisofamyloidosispart13year2020 AT posadasmartinezmarialourdes guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT aguirremariaadela guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT belziticesar guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT broueteva guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT auterimiguelangel guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT forteanaluz guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT grelonigustavo guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT marcianosebastian guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT matosomariadolores guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT perezdearenazadiego guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT pitzusarieledgardo guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT rugieromarcelo guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT saezsoledad guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT sorrochepatricia guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT tomeimauricio guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT zinserbettina guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT peuchotveronica guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT nuciforaelsa guiadepracticaclinicaparaeldiagnosticodelaamiloidosisparte13ano2020 AT posadasmartinezmarialourdes guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT aguirremariaadela guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT belziticesar guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT broueteva guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT auterimiguelangel guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT forteanaluz guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT grelonigustavo guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT marcianosebastian guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT matosomariadolores guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT perezdearenazadiego guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT pitzusarieledgardo guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT rugieromarcelo guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT saezsoledad guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT sorrochepatricia guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT tomeimauricio guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT zinserbettina guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT peuchotveronica guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 AT nuciforaelsa guiadepraticaclinicaparaodiagnosticoetipificacaodaamiloidoseparte13ano2020 |
| first_indexed |
2024-09-03T21:02:10Z |
| last_indexed |
2024-09-03T21:02:10Z |
| _version_ |
1809210230978904064 |
| spelling |
I10-R327-article-308242021-07-07T13:29:31Z Clinical Practice Guidelines for diagnosis of amyloidosis: Part 1/3 Year 2020 Guía de Práctica Clínica para el diagnóstico de la amiloidosis: Parte 1/3. Año 2020 Guia de Prática Clínica para o diagnóstico e tipificação da amiloidose: Parte 1/3. Ano 2020 Posadas Martinez, Maria Lourdes Aguirre, María Adela Belziti, Cesar Brouet, Eva Auteri, Miguel Angel Forte, Ana Luz Greloni, Gustavo Marciano, Sebastian Matoso, Maria Dolores Perez de Arenaza, Diego Pitzus, Ariel Edgardo Rugiero, Marcelo Saez, Soledad Sorroche, Patricia Tomei, Mauricio Zinser, Bettina Peuchot, Veronica Nucifora, Elsa amyloidosis diagnosis amyloidosis inmunoglobulin light-chain amyloidosis amyloidosis, familial Spanish amiloidosis diagnóstico amiloidosis; amiloidosis de cadenas ligeras de las inmunoglobulinas amiloidosis familiar amiloidose diagnóstico amiloidose de cadeia leve de imunoglobulina amiloidose familiar Español Method: Use the PICO format to generate a series of questions, focusing on the specificity and sensitivity of the amyloidosis diagnostic test. PubMed searches were conducted in English and Spanish from July to August 2019. The level of evidence and recommendation are based on the GRADE system (http://www.gradeworkinggroup.org/index.htm). The recommendations are graded according to their direction (for or against) and strength (strong and weak). Finally, it is recommended to use GLIA tools to evaluate the obstacles and facilitators in implementation. Suggested explanation: A strong suggestion indicates a high degree of trust in support or opposition to the intervention. When defining a strong recommendation, this guide uses the "recommended" language. The weaker recommendations indicate that the outcome of the intervention (favorable or unfavorable) is doubtful. In this case, if a weak recommendation is defined, the "recommendation" language is used. How to use these guidelines: Recommendations must be explained within the scope of special care in validated diagnostic studies conducted by specially trained doctors. It is not assumed to change the coexistence conditions of the disease process. Presumably, the attending physician has a high degree of suspicion of amyloidosis. It assumes that diagnostic research is conducted by well-trained doctors using a validated standardized method. This guide is intended for health care professionals and those involved in health care policies to help ensure that the necessary agreements have been reached to provide appropriate care. Recommendations For patients with suspected amyloidosis, it is recommended: Confirmation in the tissue by biopsy and Congo red staining with the characteristic green birefringence under polarized light is recommended. Confirmation by electron microscopy of the biopsy tissue is recommended. Protein typing by mass spectrometry is recommended. Protein typing by optical and / or electronic immunomicroscopy is recommended, as long as there are reliable antibodies. Measurement of serum free light chains is recommended for evaluation of a monoclonal plasma cell proliferative disorder. Serum and urinary immunofixation is recommended for evaluation of a monoclonal plasma cell proliferative disorder. Measurement of serum free light chains, plus serum and urinary immunofixation is recommended for the evaluation of a monoclonal plasma cell proliferative disorder. For patients suspected of having amyloidosis, it is suggested: Demonstration of a monoclonal plasma cell proliferative disorder by demonstration of clonal plasma cells by the most sensitive technique available in the bone marrow for the diagnosis of AL-type amyloidosis. Confirmation of ATTRv amyloidosis by DNA sequencing of the 4-exon amyloidogenic TTR gene in patients with suspected ATTRv amyloidosis. Métodos: Se generó un listado de preguntas con el formato PICO centradas en la especificidad y sensibilidad de las pruebas diagnósticas en amiloidosis. Se realizó la búsqueda en PubMed durante julio-agosto del 2019, en inglés y español. Los niveles de evidencia y los grados de recomendación se basan en el sistema GRADE (http://www.gradeworkinggroup.org/index.htm). Las recomendaciones se graduaron según su dirección (a favor o en contra) y según fuerza (fuertes y débiles). Las recomendaciones finales fueron evaluadas con la herramienta GLIA para barreras y facilitadores en la implementación de éstas. Interpretación de recomendaciones: Las recomendaciones fuertes indican alta confianza, ya sea a favor o en contra, de una intervención. En esta guía se utiliza el lenguaje “se recomienda” cuando se define una recomendación fuerte. Las recomendaciones débiles indican que los resultados para una intervención, favorable o desfavorable, son dudosos. En este caso, se utiliza el lenguaje “se sugiere”, cuando se define una recomendación débil. Como utilizar estas pautas: Las recomendaciones deben ser interpretadas en el contexto de la atención especializada, con estudios diagnósticos validados y realizados por médicos entrenados. No asume condiciones coexistentes que modificaran el curso de la enfermedad. Se asume que el médico tratante tiene alto nivel de sospecha de amiloidosis. Asume que los estudios diagnósticos son realizados por médicos entrenados con métodos validados y estandarizados. Esta guía es relevante para los profesionales de la salud y los involucrados en las políticas sanitarias, para ayudar a asegurar que existan los acuerdos necesarios para brindar la atención adecuada. Recomendaciones En pacientes con sospecha de amiloidosis se recomienda: La confirmación en el tejido mediante biopsia y tinción con rojo Congo con la característica birrefringencia verde bajo luz polarizada. La confirmación mediante microscopía electrónica en el tejido de biopsia. La tipificación de la proteína mediante espectrometría de masa. La tipificación de la proteína mediante inmunomicroscopía óptica y/o electrónica, en la medida que haya anticuerpos confiables. La medición de las cadenas livianas libres séricas para evaluación de un trastorno proliferativo de células plasmáticas monoclonales. La Inmunofijación sérica y urinaria para la evaluación de un trastorno proliferativo de células plasmáticas monoclonales. La medición de las cadenas livianas libres sérica, más la Inmunofijación sérica y urinaria para la evaluación de un trastorno proliferativo de células plasmáticas monoclonales. En pacientes con sospecha de amiloidosis se sugiere: Demostración de un trastorno proliferativo de células plasmáticas monoclonales mediante la demostración de plasmocitos clonales por la técnica más sensible disponible en la médula ósea para el diagnóstico de amiloidosis de tipo AL. La confirmación de amiloidosis ATTRv mediante secuenciación de ADN del gen TTR amiloidogénico de los 4 exones en pacientes con sospecha de amiloidosis por ATTRv Method: Replace the various forms of PICO with specific testes. Giulio bus companies before 2019, Spain and Spain. The grade certificate recommended to your system (http://www.gradeworkinggroup.org/index.htm). As the recommended classification criteria, it is recommended to you (recommended or opposed) and recommended to you (recommended to you). As recommended by FINA, it is Ferramenta, which is composed of GLIA para barreiras e facilitadores em sua Implementação. Explicação sugerida: uma sugestão forte indica um alto nível de confiança no apoio ou oposição à intervenção. Ao definir recomendações fortes, este guia usa uma linguagem "recomendada". As recomendações mais fracas indicam que o resultado da intervenção (favorável ou desfavorável) é duvidoso. Nesse caso, se uma recomendação fraca for definida, a linguagem de "recomendação" será usada. Como usar essas diretrizes: As recomendações devem ser explicadas no contexto de cuidados especializados e estudos de diagnóstico validados realizados por médicos treinados. Não tem como premissa condições de coexistência que modificarão o curso da doença. Suponha que o médico assistente suspeite de um alto nível de amiloidose. Ele presumiu que a pesquisa diagnóstica foi conduzida por médicos bem treinados usando métodos padronizados validados. Este guia se aplica a profissionais de saúde e todos os envolvidos na política de saúde para ajudar a garantir que os arranjos necessários sejam feitos para fornecer cuidados adequados. Em pacientes com suspeita de amiloidose, é recomendado: Confirmação do tecido por biópsia e coloração com vermelho do Congo com a birrefringência verde característica sob luz polarizada é recomendada. Confirmação por microscopia eletrônica do tecido da biópsia é recomendada. Tipagem de proteínas por espectrometria de massa é recomendada. Tipagem de proteínas por imunomicroscopia ótica e / ou eletrônica é recomendada, desde que haja anticorpos confiáveis. Medição das cadeias leves livres séricas é recomendada para avaliação de um distúrbio proliferativo de células plasmáticas monoclonais. Imunofixação sérica e urinária é recomendada para avaliação de um distúrbio proliferativo de células plasmáticas monoclonais. Medição das cadeias leves livres séricas, além da imunofixação sérica e urinária, é recomendada para a avaliação de um distúrbio proliferativo de células plasmáticas monoclonais. Em pacientes com suspeita de amiloidose, sugere-se: A demonstração de um distúrbio proliferativo de células plasmáticas monoclonais demonstração de plasmócitos clonais pela técnica mais sensível disponível na medula óssea para o diagnóstico de amiloidose do tipo AL. A confirmação da amiloidose ATTRv por sequenciamento de DNA do gene TTR amiloidogênico de 4 exon em pacientes com suspeita de amiloidose ATTRv. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021-03-12 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf application/pdf application/pdf application/pdf application/pdf application/pdf text/html https://revistas.unc.edu.ar/index.php/med/article/view/30824 10.31053/1853.0605.v78.n1.30824 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 78 No. 1 (2021); 74-82 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 78 Núm. 1 (2021); 74-82 Revista da Faculdade de Ciências Médicas de Córdoba; v. 78 n. 1 (2021); 74-82 1853-0605 0014-6722 10.31053/1853.0605.v78.n1 spa https://revistas.unc.edu.ar/index.php/med/article/view/30824/33318 https://revistas.unc.edu.ar/index.php/med/article/view/30824/33314 https://revistas.unc.edu.ar/index.php/med/article/view/30824/33315 https://revistas.unc.edu.ar/index.php/med/article/view/30824/33316 https://revistas.unc.edu.ar/index.php/med/article/view/30824/33312 https://revistas.unc.edu.ar/index.php/med/article/view/30824/33313 https://revistas.unc.edu.ar/index.php/med/article/view/30824/33103 Derechos de autor 2021 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |